INTRODUCTION
============

*Staphylococcus aureus (S. aureus)* is a significant human pathogen worldwide, particularly in healthcare settings. It has long been recognized as an important causative agent of skin and soft-tissue infections (SSTIs), which range from folliculitis to life-threatening conditions such as necrotizing fasciitis. The increasing prevalence of methicillin-resistant *S. aureus* (MRSA) and its ability to resist multiple drugs has posed a serious challenge.^[@bib1]^ Hospital-associated MRSA has been extensively investigated, with a high prevalence of MRSA (52.3%--76.9%) in mainland China.^[@bib2]^ However, considering China\'s vast territory, the data on SSTIs caused by community-associated methicillin-resistant *S. aureus* (CA-MRSA) are limited. Despite the importance of MRSA, methicillin-sensitive *S. aureus* (MSSA) is among the most common causative agents of SSTIs.^[@bib3]^ The epidemiological surveillance of MRSA and MSSA is critical for the development and implementation of infection control programs.

This study focused on an expanded sample of SSTI cases to obtain accurate molecular characteristics of CA-MRSA in mainland China and to produce a more comprehensive national description of the molecular epidemiology and resistance profiles of CA-MRSA in children and adults in China. Although previous studies reported on *S. aureus* biogeography and virulence,^[@bib4]^ to our knowledge, this is the first study to compare contemporaneous CA-MRSA of SSTIs from adults and children and the first such study carried out in mainland China.

MATERIALS AND METHODS
=====================

Patient enrollment
------------------

This was a laboratory-based multicenter study involving the voluntary participation of 23 hospitals (including 13 children\'s hospitals and ten adult hospitals) in six geographical regions (Northeast, North China, Northwest, East China, South Central China and Southwest) located throughout China. The inclusion criteria for these institutions were: (i) at least one children\'s hospital and one adult hospital located in five regions, but only one children\'s hospital in the Northeast area; and (ii) certified as a rank A tertiary hospital by the Ministry of Health of China. Clinical data were collected from outpatients with SSTIs in the Department of Dermatology of each hospital during a 24-month period from October 2009 to September 2011.

Clinical data collection
------------------------

Eligible patients were those with at least one sample from any site that was culture positive for *S. aureus* who met the following criteria for community-associated *S. aureus*: (i) a culture sample was obtained during an outpatient visit or within 48 h of hospitalization; (ii) the patient had not been admitted to a hospital, nursing home or any other long-term care facility within the past year; and (iii) the patient had no history within the past year of known risk factors for MRSA, including current intravenous drug use, surgery, dialysis, an indwelling catheter or a percutaneous medical device. A case report form was completed for each patient who included demographic information, clinical symptoms, laboratory findings, type of infection diagnosed, all antibiotic use and clinical outcome.

Bacterial strains
-----------------

Specimens were collected from infection sites of every patient enrolled and cultured on blood agar. Preliminary identification was performed based on bacterial morphology, Gram staining, hemolysis, and catalase tests at the central laboratory. Then, Slidex Staph Plus (bioMérieux, Marcy I\'Etoile, France) latex agglutination was performed for the rapid detection of *S. aureus*. To avoid overrepresentation, we included only the first isolate from each patient. MRSA isolates were initially identified using the oxacillin minimum inhibitory concentration method and confirmed for the presence of the *mecA* gene by PCR as previously described.^[@bib5]^

Antimicrobial susceptibility testing
------------------------------------

The minimum inhibitory concentrations of penicillin, oxacillin, cefazolin, cefuroxime, ceftriaxone, erythromycin, clindamycin, ciprofloxacin, chloramphenicol, gentamicin, rifampicin, tetracycline, trimethoprim-sulfamethoxazole, vancomycin, fusidic acid and mupirocin were determined by agar dilution method in accordance with the 2010 guidelines of the Clinical and Laboratory Standards Institutes.^[@bib6]^ All antibiotics were from Sigma Chemical Co., St Louis, MO, USA except mupirocin from GlaxoSmithKline, Brentford, London. Fusidic acid minimum inhibitory concentrations were determined according to the European Committee on Susceptibility Testing guidelines (EUCAST, version 1.3, 2010, Basel, Switzerland). The *S. aureus* strain ATCC 29213 was used as a control.

Molecular typing methods
------------------------

Staphylococcal cassette chromosome *mec* (SCC*mec*) typing, staphylococcal protein A (*spa*) typing, and multilocus sequence typing were performed using PCR as previously described for all CA-MRSA isolates.^[@bib5],\ [@bib7],\ [@bib8]^ The presence of Panton--Valentine leukocidin (*pvl)* genes, such as lukS-PV and lukF-PV, was also determined by PCR as previously described.^[@bib9]^

Statistical analysis
--------------------

A *χ*^2^-test or Fisher\'s exact test was used to analyze quantitative variables. Statistical analyses were performed using SPSS, version 13.0 software (SPSS, Chicago, IL, USA). A *P*-value of ≤0.05 was considered statistically significant. All susceptibility data and molecular test results were analyzed using WHONET software, version 5.6. StatApriori (WHO, Geneva, Switzerland) was used for searching statistically significant association rules.

RESULTS
=======

Patient demographics
--------------------

A total of 2716 patients were identified during the study period. Out of these patients, 71.6% (1946) fulfilled the criteria for inclusion in the study, 2.6% (51) met the definition of CA-MRSA infection and the rest were classified as having MSSA infection. The incidence of *S. aureus* from children\'s hospitals (82.6%, 1705/2046) was much higher than from adult hospitals (36.96%, 241/652). Common lesions in children included impetigo (81.9%, 1397/1705), staphylococcal scald skin syndrome (4.8%, 82/1705), and secondary infection of eczema (4.3%, 74/1705), whereas in adults, common lesions included secondary infection of eczema (24%, 58/241), impetigo (20%, 48/241) and folliculitis (11%, 27/241). Demographic and clinical features of all patients are shown in [Table 1](#tbl1){ref-type="table"}.

Comparison of resistance profiles of *S. aureus* isolates
---------------------------------------------------------

Overall, CA-MRSA accounted for 2.6% (51) of 1946 *S. aureus* strains. Of 1895 MSSA strains isolated, 97.3% strains were resistant to erythromycin, followed by 96.6% to penicillin, 89.1% to clindamycin, 42.0% to tetracycline and 14.4% to chloramphenicol. None of the *S. aureus* strains were resistant to vancomycin. The antimicrobial susceptibilities of MRSA isolates were compared with MSSA isolates ([Table 2](#tbl2){ref-type="table"}). CA-MRSA isolates demonstrated a higher rate of resistance to chloramphenicol, ciprofloxacin, ceftriaxone and cefixime (31.4% vs. 14.4%, 13.7% vs. 6.3%, 23.5% vs. 0.9% and 19.6% vs. 2.5%, respectively). The susceptibility profiles of MRSA to other antimicrobial agents were similar to those of MSSA. All CA-MRSA and MSSA isolates tested were sensitive to vancomycin. Significant differences in antimicrobial susceptibility profiles of isolates from children and adults were also observed (*P*\<0.05) ([Table 2](#tbl2){ref-type="table"}). *S. aureus* isolates obtained from children were more likely to be susceptible to chloramphenicol, gentamicin, ciprofloxacin, trimethoprim-sulfamethoxazole, fusidic acid, mupirocin and cephalosporin than those from adults.

Molecular characteristics of CA-MRSA isolates
---------------------------------------------

High genetic diversity was observed among the 51 CA-MRSA isolates: 13 STs and 17 *spa* types harbored two SCC*mec* types ([Table 3](#tbl3){ref-type="table"}). Surprisingly, the most prevalent ST was ST121 (19/51, 37.3%), followed by ST59 (13/51, 25.5%). Among them, t437 was predominant, which accounted for 43.1% (22/51) of all CA-MRSA isolates, followed by t2086, t1425 and t127. Only SCC*mec* type IV was found in North China. Interestingly, strains ST121, ST59 and t437 were uncommon in East China. Some spatial variations were observed in the distribution of *spa* types (e.g., t437 occurred in 66.7% and 55.6% isolates from Children\'s Hospital of Chongqing Medical University and Beijing Children\'s Hospital, respectively). However, such differences were not significant. No other clinical or spatial associations were observed in the distribution of *spa* types or STs with regard to infection type, sex, region or hospital of origin.

Of the isolates tested, only five (9.8%) of the CA-MRSA isolates harbored *pvl* genes. Four of the strains were isolated from children. Three patients suffered from abscesses, one from a furuncle and one from cellulitis. Four of the strains were t437. The clinical and molecular characteristics of the five CA-MRSA isolates are shown in [Table 3](#tbl3){ref-type="table"}.

Characteristics of ST121 CA-MRSA strains
----------------------------------------

The 19 ST121 strains were isolated from patients with impetigo (13/19), cellulitis (1/19), secondary infection of eczema (3/19) and abscess (2/19). These 19 strains comprised nine *spa* types; however, only t437 was found in ST59 strains. There was no significant difference in antibiotic sensitivities between ST121 and non-ST121 MRSA isolates. Thirty-six separate associations between the five antimicrobials (erythromycin, penicillin, tetracycline, clindamycin and cefazolin/chloramphenicol) were found. Moreover, ST121 CA-MRSA strains tended to be more resistant to cefazolin, whereas non-ST121 CA-MRSA strains tended to be more resistant to chloramphenicol ([Figure 1](#fig1){ref-type="fig"}). Two mupirocin-resistant strains were observed among non-ST121 CA-MRSA strains.

DISCUSSION
==========

This study was conducted at 23 large, inner city, comprehensive medical teaching and research hospitals selected by the Chinese Ministry of Health to fill an important gap in the knowledge of community-associated *S. aureus* SSTIs in China. To our knowledge, this is the first large-scale comparison of CA-MRSA clinical characteristics between children and adults with *S. aureus* SSTIs in mainland China. We present three major findings: (i) the prevalence of CA-MRSA was low among children and adults with SSTIs; (ii) CA-MRSA strains in China have diverse genetic backgrounds and there is no trend of an outbreak thus far; and (iii) ST121 is currently the predominant clone.

The prevalence of CA-MRSA varies geographically, with a detection rate in patients with skin infections of 1--3% in France and up to 50% in the United States.^[@bib10]^ The incidence of CA-MRSA SSTIs in China is unclear because of the lack of systematic epidemiological studies. A few small studies demonstrated that the incidence of CA-MRSA with SSTIs was 1.1--4% in Beijing and other regions of China.^[@bib11],\ [@bib12]^ In this study, we found the prevalence of CA-MRSA SSTIs to be surprisingly low, from 1.3% in North China to 6.1% in Southwest China. Furthermore, no MRSA infections were observed at two children\'s hospitals and four adult hospitals. A potential explanation for the differences in the prevalence of MRSA infections in distinct regions of China is most likely the vast size of the territories, along with disparities in economic development. Another explanation may be a data bias of fewer cases in these regions. The current absence of CA-MRSA outbreaks or reports on serious outcomes of CA-MRSA infections suggests that the low prevalence observed in this study may truly reflect the current situation in China.

Antibiogram testing is a crucial step in MRSA screening and selection of the appropriate antibiotic for proper treatment of skin infections. Our study showed that most patients had MSSA (1 964/2 716 patients). On comparing the antibiotic susceptibility patterns of bacterial isolates from children and adults, significant differences were found. Antibiotic susceptibility patterns therefore appear to depend mainly on bacterial strains, rather than type of skin infections. The majority of patients with SSTIs can be cured only using topical antibiotics; however, a small number of patients require systematic treatment. According to the results of antibiotic susceptibility tests in this study, penicillin and erythromycin are no longer appropriate agents, and cephalosporin may be the wiser choice. Although MRSA are generally resistant to all previously available beta-lactams, it was interesting that cephalosporin demonstrated potent activity against CA-MRSA. Indeed, traditional antistaphylococcal antibiotics (cephalosporin) have been associated with good clinical outcomes for CA-MRSA SSTIs. Recently, ceftaroline, which is a novel parenteral broad-spectrum cephalosporin, demonstrated bactericidal activity against Gram-positive organisms (including MRSA) and represented a bactericidal option for the treatment of MRSA infections, including those caused by isolates with reduced susceptibilities to vancomycin and daptomycin.^[@bib13]^

Fusidic acid and mupirocin are effective topical antibacterial agents for the management of skin infections and *S. aureus* colonization in both patients and healthcare workers. In the past decade, there has been an increase in fusidic acid resistance in a number of countries. However, the fusidic acid resistance rates between MSSA and MRSA may differ. From 1998 to 2001, data from the United Kingdom showed that the resistance rates for fusidic acid in MSSA increased from 6.0% to 11.5%, whereas the resistance rates in MRSA were much lower and remained constant at \~2%.^[@bib14]^ In this study, we also found it interesting that only MSSA was resistant to fusidic acid (1.4%). In 1999, fusidic acid was first introduced in China and has been available as a topical cream since 2003. However, resistance to fusidic acid in China was reported after 2007.^[@bib15],\ [@bib16]^ Therefore, selective pressure from antibiotic use likely led to increased resistance to fusidic acid. Similarly, initial reports on mupirocin-resistant *S. aureus* emerged shortly after the introduction of mupirocin into clinical practice.^[@bib17]^ However, the prevalence of mupirocin resistance has increased in settings where this agent is used extensively. It has been reported that more than 50% of community-associated *S. aureus* strains displayed high-level resistance to mupirocin in Canada.^[@bib18]^ In Beijing Children\'s Hospital, mupirocin ointment has been prescribed since 1993. However, only one strain was found to be resistant to mupirocin in 2005.^[@bib15]^ In this study, the number of mupirocin-resistant *S. aureus* isolates clearly increased, but remained low compared with rates observed in other countries. Mupirocin therefore remains an effective therapy for the elimination of staphylococci in China.

It has been reported that five major CA-MRSA clones are disseminating worldwide. For example, the ST1 clone is observed in Asia, Europe, and the United States; the ST8 clone in Europe and the United States; the ST30 clone in Australia, Europe and South America; the ST59 clone in Asia and the United States; and the ST80 clone in Asia, Europe, and the Middle East.^[@bib19]^ In 2007, Schefold *et al.*^[@bib20]^ first reported a sepsis case of a 51-year-old male caused by *S. aureus* ST121. Thereafter, ST121 MSSA isolates were found to be distributed in 15 out of the 19 surveyed countries, namely Paraguay, New Caledonia, Togo, France, Czech Republic, Germany, Turkey, the United States, French West Indies, United Kingdom, Polynesia, Switzerland, Spain, Algeria and The Netherlands.^[@bib21]^ A small study performed in mainland China demonstrated that \~8.3% (1/12) of SSTIs^[@bib22]^ and 30.6% of asymptomatically colonized children in kindergartens^[@bib23]^ were associated with ST121 isolates. These findings suggest that most ST121 strains are MSSA. The ST121 clone is rarely dominant in MRSA clinical infections. It has been reported that 11.8% of MRSA strains belonged to ST121 in Cambodia,^[@bib24]^ 7.1% in Japan,^[@bib25]^ 5.4% in Portugal^[@bib26]^ and 0.3% in Spain.^[@bib27]^ The important finding from the present study is that ST121 (35.3%), which had been previously documented in only two isolates (3.5%) among MRSA causing SSTIs in 2015,^[@bib28]^ was more prevalent than ST59 (25.5%). Moreover, ST121 isolates have disseminated in seven hospitals located in five regions in mainland China. Interestingly, neither ST121 nor ST59 was observed in East China hospitals, an area of relatively rapid economic development. In addition, predominant *spa* type t437, which comprised 43.2% of all CA-MRSA, was also not observed in East China. There were also no significant differences in antibiotic sensitivities between MRSA and MSSA. MSSA has evolved as MRSA through the acquisition of SCC*mec,*^[@bib29],\ [@bib30]^ and therefore, some MSSA genotypes are the same as some popular CA-MRSA genotypes. Baines *et al.*^[@bib31]^ found that ST5 MRSA clone has emerged from locally circulating ST5 MSSA strains in New Zealand. In addition, Stegger *et al.*^[@bib32]^ determined that a single descendant of a PVL-positive methicillin-sensitive ancestor circulating in sub-Saharan Africa rose to become the dominant CA-MRSA clone in Europe, the Middle East and North Africa. The findings in this study indicate that the genetic background of CA-MRSA found in mainland China is complex. We will next probe more deeply into the genotyping of MSSA and expect to find clues of MRSA \'conversion\' from MSSA in China.

The role of PVL in the pathogenesis of staphylococcal infections remains controversial. However, PVL has been closely associated with CA-MRSA infections, and there is a strong epidemiological association between carriage of *pvl* genes and successful CA-MRSA lineages. PVL-positive *S. aureus* strains are more frequently associated with cellulitis and abscesses than with impetigo.^[@bib33]^ Although highly virulent CA-MRSA strains carrying *pvl* genes are known to prevail worldwide, the prevalence of PVL-positive MRSA strains from SSTIs in China was reported to range from 12.5% to 19.1%.^[@bib28],\ [@bib34]^ Compared with a previous study, the overall positivity rates of *pvl* genes in the present study was lower (9.8%), indicating a decreased prevalence of *pvl* genes among *S. aureus* SSTI isolates in China. Five patients with PVL-positive CA-MRSA infections were able to perform daily activities and had no identifiable risk factors. All five patients were empirically treated with cephalosporin and good outcomes were achieved.

In summary, this study provided information on the epidemiological and molecular characteristics of community-acquired *S. aureus* SSTIs among Chinese populations. The low prevalence of CA-MRSA is positive news. Interestingly, ST121 was the predominant clone among CA-MRSA strains. Moreover, there were no clear regional variations. To fully understand the epidemiology of *S. aureus* clone ST121, the continued systematic surveillance of both hospital- and community-associated isolates is required.
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###### Demographic and clinical features of patients from children and adults with skin and soft-tissue infections

  **Variables**                                              **Children**           **Adults**
  --------------------------------------------------------- -------------- -----------------------------
  *General information*                                                    
   Total patients (*n*)                                          2046                   670
   Male to female ratio                                         1.25:1                1.24:1
   Age (mean±SD, years)                                       3.69±2.67             29.43±22.25
   Range                                                     1 d to 18 y             19--93 y
   MSSA (*n*)                                                    1705                   241
   MRSA (*n*)                                                     44                     7
                                                                           
  *Types of skin and soft-tissue infection (n) (SA/MRSA)*                  
  * Diseases*                                                              
    Impetigo                                                   1397/28                 48/1
    SSSS                                                         82/2                   0/0
    Secondary infection of eczema                                74/2                  58/1
    Abscess                                                      28/5                  13/3
    Secondary infection of urticaria-like papules                27/0                   0/0
    Folliculitis                                                 21/1                  27/0
    Furuncle                                                     10/1                  14/1
    Cellulitis                                                   9/2                    2/0
    Paronychia                                                   4/1                    0/0
    Trauma                                                       4/0                    8/1
    Omphalitis                                                   2/1                    0/0
    Necrotizing fasciitis                                        1/0                    0/0
    Other secondary infections                                   46/1                  71/0
  **Region**                                                 **Hospital**   **(*n*) (patient/SA/MRSA)**
  *Source and distribution of patients*                                    
   Northeast                                                     HBCH                187/142/6
                                                                 CCCH                 23/10/2
                                                                 DLCH                  9/8/0
   North China                                                   PPH                  35/8/0
                                                                 PTH                  30/11/0
                                                                 PFH                  71/28/2
                                                                 BJCH                826/787/9
                                                                 SXCH                 90/69/1
                                                                 TJCH                  5/5/0
   East China                                                    HSH                  18/6/0
                                                                 XZCH                204/163/2
                                                                 FDPH                 35/26/1
   Northwest                                                     XJH                  94/34/1
                                                                 UFH                  89/52/1
                                                                 XJFH                 50/33/1
   Southwest                                                     WCH                  90/17/1
                                                                 SWH                  94/46/0
                                                                 CQCH                116/102/9
   South Central China                                           WHH                  66/11/1
                                                                 XYH                  83/28/1
                                                                 ZZCH                196/153/3
                                                                 HNCH                131/82/2
                                                                 GZCC                174/125/8

Abbreviations: methicillin-resistant *Staphylococcus aureus*, MRSA; methicillin-sensitive *S. aureus*, MSSA; *Staphylococcus aureus*, SA.

Three letter abbreviations for adult\'s hospital and four letter abbreviations for children\'s hospital: Beijing Children\'s Hospital, BJCH; Children\'s Hospital of Changchun, CCCH; Children\'s Hospital of Chongqing Medical University, CQCH; Dalian Children\'s Hospital of Dalian Medical University, DLCH; The Paediatric Hospital of Fudan University, FDPH; Harbin Children\'s Hospital, HBCH; Hunan Children\'s Hospital, HNCH; Huashan Hospital of Fudan University, HSH; Guangzhou Women and Children\'s Medical Center, GZCC; Peking University First Hospital, PFH; Peking University; People\'s Hospital, PPH; Peking University Third Hospital, PTH; The First People\'s Hospital of Urumqi, UFH; Southwest Hospital, SWH; Children\'s Hospital of Shanxi, SXCH; Tianjin Children\'s Hospital, TJCH; West China Hospital, WCH; Wuhan No.1 Hospital, WHH; The First Affiliated Hospital of Xinjiang Medical University, XJFH; Xijing Hospital, XJH; The Second Xiangya Hospital of Central South University, XYH; Xuzhou Children\'s Hospital, XZCH; Zhengzhou Children\'s Hospital, ZZCH.

###### Results of the susceptibility testing of the strains

  **Agents**                      **Children (*n*=1705)**   **Adults (*n*=241)**    ***P***    **MRSA (*n*=51)**   **MSSA (*n*=1895)**   ***P***
  ------------------------------- ------------------------- ---------------------- ---------- ------------------- --------------------- ----------
  Penicillin G                    96.8                      87.9                    *P*≤0.05          100                 96.6            0.412
  Erythromycin                    96.8                      86.6                    *P*≤0.05          98                  97.3              1
  Clindamycin                     89.3                      70.7                    *P*≤0.05         86.3                 89.1            0.528
  Tetracycline                    38.8                      31.8                     0.041            49                   42             0.317
  Chloramphenicol                 15.1                      24.8                    *P*≤0.05         31.4                 14.4           *P*≤0.05
  Gentamicin                      9.6                       29.3                    *P*≤0.05          5.9                  9.9            0.339
  Ciprofloxacin                   6.2                       20.4                    *P*≤0.05         13.7                  6.3           *P*≤0.05
  Trimethoprim/sulfamethoxazole   3.6                       7.6                      0.004            7.8                  4.5            0.291
  Oxacillin                       2.6                       1.9                      0.639            100                   0               /
  Fusidic acid                    1.8                       7                       *P*≤0.05           0                   1.4              1
  Rifampin                        1.7                       2.7                      0.194            3.9                  2.4            0.351
  Cefazolin                       1.4                       6.4                     *P*≤0.05          3.9                  1.6            0.204
  Mupirocin                       1.3                       5.8                     *P*≤0.05          3.9                  0.7            0.057
  Ceftriaxone                     1.1                       4.5                     *P*≤0.05         23.5                  0.9           *P*≤0.05
  Cefixime                        0.5                       5.7                     *P*≤0.05         19.6                  2.5           *P*≤0.05
  Vancomycin                      0                         0                          /               0                    0               /

Abbreviations: methicillin-resistant *Staphylococcus aureus*, MRSA; methicillin-sensitive *S. aureus*, MSSA.

###### Clinical and molecular features of 51 cases with CA-MRSA infections

  **Number**   **Case**   **Hospital**   **Infection**                           **MLST**   **SPA**    **SCC*mec***   **PVL**
  ------------ ---------- -------------- --------------------------------------- ---------- --------- -------------- ---------
  1            XZ40A      XZCH           Impetigo                                st1        t127            V            −
  2            C490       BJCH           Impetigo                                st121      t1425           IV           −
  3            C668       BJCH           Impetigo                                st121      t2086           IV           −
  4            C958       BJCH           Impetigo                                st121      t2086           V            −
  5            C732       BJCH           Impetigo                                st121      t437            V            −
  6            C1243      BJCH           Impetigo                                st338      t437            V            −
  7            C871       BJCH           Impetigo                                st448      t1425           IV           −
  8            C867       BJCH           Paronychia                              st59       t437            IV           −
  9            C1252      BJCH           Impetigo                                st59       t437            V            −
  10           C152       BJCH           Impetigo                                st59       t437            IV           −
  11           CC18       CCCH           Impetigo                                st121      t2019           IV           −
  12           CC16       CCCH           Impetigo                                st573      t1839           V            −
  13           CCH40      CQCH           Impetigo                                st121      t1425           V            −
  14           CCH42      CQCH           Impetigo                                st211      t437            V            −
  15           CCH115     CQCH           Abscess                                 st45       t2086           V            −
  16           CCH184     CQCH           Abscess                                 st59       t437            IV           −
  17           CCH229     CQCH           Impetigo                                st59       t437            V            −
  18           CCH118     CQCH           Abscess                                 st121      t2086           IV          \+
  19           CCH302     CQCH           Cellulitis                              st121      t437            IV          \+
  20           CCH193     CQCH           Abscess                                 st59       t437            V           \+
  21           CCH117     CQCH           Abscess                                 st121      t437            IV            
  22           EK16       FDPH           Impetigo                                st8        t008            V            −
  23           GCH43      GZCC           Impetigo                                st121      t1425           IV           −
  24           GCH36      GZCC           Impetigo                                st121      t2086           IV           −
  25           GCH291     GZCC           Impetigo                                st121      t269            IV           −
  26           GCH92      GZCC           Impetigo                                st121      t375            V            −
  27           GCH268     GZCC           Impetigo                                st121      t8660           V            −
  28           GCH52      GZCC           Secondary infection of herpes simplex   st338      t437            V            −
  29           GCH101     GZCC           SSSS                                    st448      t437            IV           −
  30           GCH35      GZCC           Furuncle                                st338      t437            V           \+
  31           HCH37C     HBCH           Impetigo                                st121      t127            IV           −
  32           HCH249     HBCH           Secondary infection of eczema           st121      t2086           V            −
  33           HCH233     HBCH           Secondary infection of eczema           st121      t437            V            −
  34           HCH68C     HBCH           Impetigo                                st211      t1425           V            −
  35           HCH23      HBCH           Impetigo                                st59       t437            IV           −
  36           HCH65C     HBCH           Impetigo                                st59       t437            V            −
  37           HN104      HNCH           Omphalitis                              st19       t30             V            −
  38           HN133      HNCH           Cellulitis                              st20       t2919           V             
  39           BHC108     PFH            Impetigo                                st88       t7637           IV           −
  40           BHC123     PFH            Abscess                                 st59       t437            IV          \+
  41           SX75       SXCH           Impetigo                                st121      t2086           IV           −
  42           XJC41      UFH            Impetigo                                st59       t437            IV           −
  43           CDL13      WCH            Trauma                                  st1        t127            IV           −
  44           WH54       WHH            Abscess                                 st59       t437            IV           −
  45           XJH31      XJFH           Furuncle                                st59       t437            IV           −
  46           XJ74       XJH            Secondary infection of eczema           st121      t114            IV           −
  47           XYH34      XYH            Abscess                                 st59       t437            V            −
  48           XZ107      XZCH           Folliculitis                            st88       t325            IV           −
  49           ZCH13C     ZZCH           Impetigo                                st1        t127            V            −
  50           ZCH03      ZZCH           Impetigo                                st1        t1784           IV           −
  51           ZCH18A     ZZCH           SSSS                                    st93       t202            V            −

Abbreviations: community-associated methicillin-resistant *Staphylococcus aureus*, CA-MRSA; multilocus sequence typing, MLST; panton-valentine leukocidin, PVL; Staphylococcal cassette chromosome *mec*, SCC*mec*; staphylococcal protein A, SPA.
